Nanodelivery strategies for the treatment of multidrug-resistant bacterial infections.
Nanodelivery strategies for the treatment of multidrug-resistant bacterial infections.
复制标题
DOI：
10.1002/jin2.48
复制
发表时间：
2018-09
期刊：
影响因子：
--
通讯作者：
Scott CJ
中科院分区：
文献类型：
--
作者：
Jiang L;Lin J;Taggart CC;Bengoechea JA;Scott CJ
社会中最重要的健康问题之一是由多重耐药病原体引起的医院感染的发展。本文综述了ESKAPE病原体感染的抗生素治疗现状，以及ESKAPE病原体感染治疗新策略的研究进展。ESKAPE病原体包括屎肠球菌（Enterococcus faecium）、金黄色葡萄球菌（Staphylococcus aureus）、肺炎克雷伯菌（Klebsiella pneumoniae）、鲍曼不动杆菌（Acinetobacter baumannii）、铜绿假单胞菌（Pseudomonas aeruginosa）和肠杆菌属（Enterobacter species）。我们不仅研究了目前由多药耐药性引起的问题，而且还研究了这些病原体为避免抗生素暴露而利用的屏障效应，如生物膜和细胞内定位。综述了纳米医学方法和抗体抗生素缀合物的最新创新，作为治疗细菌感染的潜在新方法，最终可能会延长当前抗生素的使用寿命。
One of the most important health concerns in society is the development of nosocomial infections caused by multidrug‐resistant pathogens. The purpose of this review is to discuss the issues in current antibiotic therapies and the ongoing progress of developing new strategies for the treatment of ESKAPE pathogen infections, which is acronymized for Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species. We not only examine the current issues caused by multidrug resistance but we also examine the barrier effects such as biofilm and intracellular localization exploited by these pathogens to avoid antibiotic exposure. Recent innovations in nanomedicine approaches and antibody antibiotic conjugates are reviewed as potential novel approaches for the treatment of bacterial infection, which ultimately may expand the useful life span of current antibiotics.